Navigation

Skiplink Navigation

Main Features

Serono bids for French biotech firm

Serono looks to expand product pipeline by acquiring Genset [photo: Serono]

The Swiss biotechnology firm, Serono, has offered SFr157.9 million ($105.9 million) to take over the French genomics-based biotech company, Genset.

"The offer for Genset is a continuation of our strategy of selective research and development investments," said Ernesto Bertarelli, CEO of Serono, in a statement released on Wednesday.

"This investment will further develop our genomics drug discovery platform and feed our pipeline," he added.

The Geneva-based firm has offered cash for all outstanding shares in the French company at a rate of €9.75 per Genset share.

At an extraordinary general meeting on Wednesday, Genset's shareholders followed recommendations by the company's board to accept the offer.

swissinfo with agencies


Links

Neuer Inhalt

Horizontal Line


swissinfo EN

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

Join us on Facebook!

subscription form

Form for signing up for free newsletter.

Sign up for our free newsletters and get the top stories delivered to your inbox.







Click here to see more newsletters